Glaxosmithkline Llc Pac (Gsk Pac) FEB MONTHLY Filings
Cycle | Date Filed | End Date | Amendment | Receipts | Spending | Cash |
---|---|---|---|---|---|---|
2024 | Feb. 20 | Jan. 31 | $23,225.35 | $77.17 | $49,317.34 | |
2024 | Feb. 15, 2023 | Jan. 31, 2023 | $22,666.73 | $107.65 | $64,856.10 | |
2022 | March 17, 2022 | Jan. 31, 2022 | Compare to original | $24,412.30 | $80.37 | $142,640.71 |
2022 | Feb. 5, 2021 | Jan. 31, 2021 | $24,478.32 | -$21,669.21 | $136,390.24 | |
2020 | Feb. 11, 2020 | Jan. 31, 2020 | $24,995.06 | $9,132.38 | $182,261.40 | |
2020 | Feb. 20, 2019 | Jan. 31, 2019 | $27,942.18 | $2,606.70 | $148,055.15 | |
2018 | Feb. 20, 2018 | Jan. 31, 2018 | $32,460.17 | $242.94 | $120,678.09 | |
2018 | Feb. 20, 2017 | Jan. 31, 2017 | $31,034.31 | $222.31 | $114,605.57 | |
2016 | Feb. 19, 2016 | Jan. 31, 2016 | $45,801.31 | $402.75 | $173,572.96 | |
2016 | Feb. 20, 2015 | Jan. 31, 2015 | $59,858.01 | $143.79 | $196,355.31 | |
2014 | Feb. 19, 2014 | Jan. 31, 2014 | $63,154.28 | -$300.42 | $185,130.28 | |
2014 | Feb. 19, 2013 | Jan. 31, 2013 | $42,300.31 | $1,287.27 | $113,120.69 | |
2012 | Feb. 20, 2012 | Jan. 31, 2012 | $42,846.65 | -$3,687.60 | $117,969.02 | |
2012 | Feb. 15, 2011 | Jan. 31, 2011 | $46,145.15 | $3,295.44 | $148,147.50 | |
2010 | Feb. 18, 2010 | Jan. 31, 2010 | $63,551.09 | $5,119.11 | $197,621.09 | |
2010 | Sept. 18, 2009 | Jan. 31, 2009 | Compare to original | $72,000.15 | $5,262.34 | $176,410.37 |
2008 | Sept. 18, 2009 | Jan. 31, 2008 | Compare to original | $75,815.00 | $57,380.00 | $157,577.00 |
2008 | Feb. 20, 2007 | Jan. 31, 2007 | $77,926.36 | $26,792.86 | $203,583.88 | |
2006 | Sept. 28, 2006 | Jan. 31, 2006 | Compare to original | $81,415.76 | $12,355.00 | $534,615.02 |
2006 | Feb. 16, 2005 | Jan. 31, 2005 | $83,183.50 | $38,500.00 | $278,714.00 | |
2004 | Feb. 19, 2004 | Jan. 31, 2004 | $116,875.00 | $3,825.00 | $396,843.00 | |
2004 | Feb. 14, 2003 | Jan. 31, 2003 | View | View | ||
2002 | March 19, 2002 | Jan. 31, 2002 | View | View | ||
2002 | Feb. 14, 2001 | Jan. 31, 2001 | View | View |